A citation-based method for searching scientific literature

Surakit Nathisuwan, Robert L Talbert. Pharmacotherapy 2002
Times Cited: 35

Jessie Gu, Adele Noe, Priya Chandra, Suliman Al-Fayoumi, Monica Ligueros-Saylan, Ramesh Sarangapani, Suzanne Maahs, Gary Ksander, Dean F Rigel, Arco Y Jeng, Tsu-Han Lin, Weiyi Zheng, William P Dole. J Clin Pharmacol 2010
Times Cited: 355

List of shared articles

Times cited

Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?
Vasiliki Katsi, Georgios Skalis, Antonis N Pavlidis, Thomas Makris, Petros Nihoyannopoulos, Dimitris Tousoulis, Ioannis Kallikazaros. Eur Heart J Cardiovasc Pharmacother 2015

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice.
Ya Suo, Meng Yuan, Hongmin Li, Yue Zhang, Ying Li, Huaying Fu, Fei Han, Changhui Ma, Yuanyuan Wang, Qiankun Bao,[...]. Front Pharmacol 2019

Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
Yue Zhang, Meng Yuan, Ya Suo, Qian Yang, Shuai Shao, Ying Li, Yuanyuan Wang, Qiankun Bao, Tong Liu, Guangping Li. Clin Exp Pharmacol Physiol 2022

Role of Neprilysin Inhibitors in Heart Failure.
Juan P Salazar Adum, Rohit Arora. Am J Ther 2017

Natriuretic peptides and cardio-renal disease.
Massimo Volpe. Int J Cardiol 2014

In silico study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor.
Jelena Đorović Jovanović, Marko Antonijević, Radiša Vojinović, Nenad D Filipović, Zoran Marković. RSC Adv 2022

The Mechanism of Action of LCZ696.
Juan Tamargo Menendez. Card Fail Rev 2016